{"id":"W3135084125","doi":"10.1200/jco.2021.39.6_suppl.93","title":"TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Enzalutamide; Oncology; Clinical endpoint; Taxane; Urology; Cancer; Surgery; Clinical trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001158113,0.001209225,0.001009821,0.000392218,0.0002872353,0.001027357,0.0007285101,0.0008870778,0.006421019],"category_scores_gemma":[0.0007576055,0.000438131,0.00105821,0.0003734946,0.0005853463,0.0007779481,0.0004000064,0.002346748,0.001286058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007725242,"about_ca_system_score_gemma":0.001181214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001015004,"about_ca_topic_score_gemma":0.002831921,"domain_scores_codex":[0.9997718,0.00009199302,0.0000114363,0.00004335773,0.00002730363,0.00005419142],"domain_scores_gemma":[0.9995375,0.00005437397,0.00007525767,0.00002012802,0.00003020531,0.0002826292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7453056,0.05370335,0.01480434,0.001752806,0.002398614,0.0005560638,0.000390406,0.004231168,0.03925261,0.0007974884,0.01474376,0.1220639],"study_design_scores_gemma":[0.7089689,0.2618173,0.01603486,0.00007877081,0.001024332,0.0007144302,0.0001145197,0.002094566,0.003025721,0.0005292446,0.005553947,0.00004329101],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822031,0.003176999,0.000688596,0.001075251,0.0001488553,0.003930813,0.003527076,0.0001806899,0.005068703],"genre_scores_gemma":[0.9815978,0.002109899,0.001331582,0.001787293,0.0001782557,0.002687034,0.005859048,0.00004116598,0.004407959],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006421019,"threshold_uncertainty_score":0.0214805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123420876443184,"score_gpt":0.486399985070088,"score_spread":0.3740578974257696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}